|4Feb 23, 8:55 PM ET

Danahy Kevin Patrick 4

4 · PULSE BIOSCIENCES, INC. · Filed Feb 23, 2026

Research Summary

AI-generated summary of this filing

Updated

Pulse Biosciences CCO Kevin Danahy Exercises Options, Sells Shares

What Happened

  • Kevin Patrick Danahy, Chief Commercial Officer of Pulse Biosciences (PLSE), exercised 5,000 stock options at $1.53 per share (cost $7,650) on Feb 18, 2026 and sold 5,000 shares in an open-market transaction that generated approximately $118,200 (weighted average price $23.64). The Form 4 also reports a derivative disposition of 5,000 shares at $0.00 (reported as an M-code derivative disposition).
  • This sequence (exercise followed by sale) is consistent with an option exercise and immediate sale of the resulting shares — a routine monetization rather than an outright open-market purchase.

Key Details

  • Transaction date: Feb 18, 2026; Form 4 filed Feb 23, 2026.
  • Exercise: 5,000 shares at $1.53 each = $7,650 (code M).
  • Sale: 5,000 shares sold, weighted avg price $23.64, total proceeds $118,200; actual sale prices ranged $22.40–$24.40 per share (footnote F2).
  • Additional line: 5,000-share derivative disposition at $0.00 (reported as M — see context below).
  • Notable footnotes:
    • F1: Transactions were effected under a Rule 10b5-1 trading plan adopted May 14, 2025.
    • F2: Weighted-average sale price; reporting person can provide a breakdown of shares sold at each price within the $22.40–$24.40 range upon request.
    • F3: The options exercised were part of a grant (9/23/2022) of up to 450,000 shares tied to a promotion and vesting schedule.
  • Shares owned after the transaction are not specified in the provided summary of this filing.

Context

  • The filing shows an option exercise (M) and an immediate open-market sale of the resulting shares — a common way for insiders to realize gains from vested options. The separate derivative disposition entry at $0.00 often reflects share surrender or adjustment related to the exercise (for example, to cover taxes or option costs), though the Form 4 does not elaborate.
  • The sale was executed under a pre-established 10b5-1 plan, which can indicate pre-planned transactions rather than opportunistic trading based on current company developments.

Insider Transaction Report

Form 4
Period: 2026-02-18
Danahy Kevin Patrick
Chief Commercial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-02-18$1.53/sh+5,000$7,65048,298 total
  • Sale

    Common Stock

    [F1][F2]
    2026-02-18$23.64/sh5,000$118,20043,298 total
  • Exercise/Conversion

    Stock Option (right to buy)

    [F1][F3]
    2026-02-185,000300,000 total
    Exercise: $1.53Exp: 2032-09-23Common Stock (5,000 underlying)
Footnotes (3)
  • [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025.
  • [F2]The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $22.40 to $24.40 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range.
  • [F3]Options granted on September 23, 2022, to acquire up to 450,000 shares of Common Stock, in connection with reporting person's promotion, with 25% vesting on each anniversary of grant, pursuant to the terms of an amendment to reporting person's Employment Agreement dated February 9, 2022.
Signature
/s/ Kenneth B. Stratton, as Attorney-in-Fact|2026-02-23

Documents

1 file
  • 4
    rdgdoc.xmlPrimary

    FORM 4